

John G Gribben

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6465868/john-g-gribben-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

568
papers

25,278
citations

90
h-index

148
g-index

588
ext. papers

28,404
ext. citations

5.4
avg, IF

6.7
L-index

#	Paper	IF	Citations
568	Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. <i>Science</i> , 1993 , 262, 909-11	33.3	793
567	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2004 , 351, 893-901	59.2	754
566	Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. <i>New England Journal of Medicine</i> , 1991 , 325, 1525-33	59.2	566
565	Genetic and Functional Drivers of Diffuse Large BCell Lymphoma. <i>Cell</i> , 2017 , 171, 481-494.e15	56.2	499
564	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. <i>Nature Genetics</i> , 2014 , 46, 176-181	36.3	475
563	Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 6586-90	11.5	468
562	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2427-37	15.9	426
561	Transplantation of anergic histoincompatible bone marrow allografts. <i>New England Journal of Medicine</i> , 1999 , 340, 1704-14	59.2	384
560	B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 6575-9	11.5	375
559	T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. <i>Blood</i> , 2013 , 121, 1612-21	2.2	344
558	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 43-56	21.7	315
557	Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. <i>Blood</i> , 2008 , 112, 568-75	2.2	308
556	Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. <i>Journal of Experimental Medicine</i> , 1993 , 178, 2185-92	16.6	308
555	Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. <i>Journal of Experimental Medicine</i> , 1991 , 174, 625-31	16.6	298
554	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 799-804	2.2	296
553	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999 , 94, 3325-3333	2.2	295
552	CTLA4 mediates antigen-specific apoptosis of human T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 811-5	11.5	290

551	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. <i>Science</i> , 1994 , 266, 1039-42	33.3	286
550	Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1288-94	2.2	278
549	CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. <i>Journal of Clinical Investigation</i> , 1997 , 100, 2757-65	15.9	278
548	Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. <i>Blood</i> , 2010 , 115, 1976-84	2.2	269
547	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. <i>Blood</i> , 2012 , 120, 1412-21	2.2	264
546	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
545	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247
544	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 1081-1093	21.7	224
543	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1797-805	15.9	221
542	Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. <i>Tissue Antigens</i> , 1998 , 52, 359-67		220
541	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 16096	51.1	219
540	FLT3 mutations in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2004 , 103, 3544-6	2.2	215
539	Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. <i>Journal of Clinical Oncology</i> , 2006 , 24, 437-43	2.2	212
538	Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. <i>Clinical Infectious Diseases</i> , 2006 , 43, 16-24	11.6	210
537	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , 2013 , 122, 3165-8	2.2	208
536	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. <i>Seminars in Cancer Biology</i> , 2014 , 24, 71-81	12.7	203
535	Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5052-9	2.2	192
534	Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 11059-63	11.5	187

533	Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 8200-4	11.5	183
532	Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. <i>Blood</i> , 2009 , 114, 4713-20	2.2	182
531	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 4389-96	2.2	182
530	Phase I study of recombinant human CD40 ligand in cancer patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3280-7	2.2	182
529	T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001 , 98, 934-9	2.2	174
528	Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. <i>Lancet, The</i> , 1990 , 335, 434-7	4.0	173
527	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1188-1199	2.2	165
526	Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2803-11	2.2	165
525	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162
524	High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. <i>Journal of Clinical Oncology</i> , 1998 , 16, 13-8	2.2	161
523	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3128-35	2.2	159
522	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014 , 124, 3841-9	2.2	158
521	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018 , 8, 304-319	24.4	157
520	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. <i>Nature Medicine</i> , 2000 , 6, 667-72	50.5	155
519	How I treat CLL up front. <i>Blood</i> , 2010 , 115, 187-97	2.2	154
518	Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. <i>Blood</i> , 2009 , 114, 3909-16	2.2	153
517	Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. <i>Nature Medicine</i> , 1996 , 2, 1367-70	50.5	151
516	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. <i>Cancer Research</i> , 2009 , 69, 5424-32	10.1	141

515	HIF-2 α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. <i>Cell Stem Cell</i> , 2013 , 13, 549-63	18	136
514	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 203-11	2.2	135
513	Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020 , 20, 285-298	31.3	134
512	5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5208-12	2.2	134
511	The role of B7 family molecules in hematologic malignancy. <i>Blood</i> , 2013 , 121, 734-44	2.2	132
510	Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. <i>Clinical Cancer Research</i> , 2005 , 11, 4430-6	12.9	127
509	Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. <i>Current Opinion in Immunology</i> , 1994 , 6, 797-807	7.8	127
508	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016 , 538, 518-522	50.4	122
507	Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017 , 32, 324-341.e6	24.3	121
506	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2722-2729	2.2	120
505	Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. <i>Blood</i> , 2013 , 122, 2856-63	2.2	120
504	Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. <i>PLoS ONE</i> , 2013 , 8, e76781	3.7	119
503	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016 , 48, 183-836.3	36.3	116
502	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002 , 117, 828-34	4.5	116
501	Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1-12	16.6	114
500	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1349-55	2.2	113
499	Ex Vivo Generation of Human Anti-Bre-B Leukemia-Specific Autologous Cytolytic T Cells. <i>Blood</i> , 1997 , 90, 549-561	2.2	113
498	Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. <i>Journal of Clinical Oncology</i> , 1989 , 7, 1621-9	2.2	112

497	B7-mediated costimulation and the immune response. <i>Blood Reviews</i> , 1996 , 10, 111-27	11.1	109
496	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. <i>Nature</i> , 2014 , 514, 112-6	50.4	107
495	Disease evolution and outcomes in familial AML with germline CEBPA mutations. <i>Blood</i> , 2015 , 126, 1214-23	22.3	104
494	Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. <i>Blood</i> , 2009 , 113, 3553-7	2.2	104
493	Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. <i>Blood</i> , 2002 , 100, 2123-31	2.2	103
492	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34	27.4	102
491	EZH2 Y641 mutations in follicular lymphoma. <i>Leukemia</i> , 2011 , 25, 726-9	10.7	102
490	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2483-91	2.2	100
489	Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1056-64	4.7	99
488	E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 6250-5	11.5	96
487	Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. <i>Blood</i> , 2010 , 115, 5053-6	2.2	96
486	CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. <i>Journal of Experimental Medicine</i> , 1994 , 180, 1665-73	16.6	96
485	Risk categories and refractory CLL in the era of chemoimmunotherapy. <i>Blood</i> , 2012 , 119, 4101-7	2.2	95
484	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997 , 11, 1793-8	10.7	94
483	Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. <i>Blood</i> , 2013 , 121, 2704-14	2.2	92
482	Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. <i>Clinical Cancer Research</i> , 2013 , 19, 6686-95	12.9	91
481	GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. <i>Blood</i> , 2010 , 115, 3939-48	2.2	91
480	Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1236-41	2.2	90

479	P110 β -mediated constitutive PI3K signaling limits the efficacy of p110 β -selective inhibition in mantle cell lymphoma, particularly with multiple relapse. <i>Blood</i> , 2013 , 121, 2274-84	2.2	90
478	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. <i>Leukemia Research</i> , 2005 , 29, 1253-7	2.7	90
477	Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 13576-81	11.5	88
476	Update on therapy of chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 544-50	2.2	88
475	RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. <i>Nature Immunology</i> , 2016 , 17, 1352-1360	19.1	86
474	In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation. <i>Blood</i> , 1997 , 90, 4297-4306	2.2	86
473	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. <i>Leukemia</i> , 2016 , 30, 570-9	10.7	85
472	Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?. <i>Genomics</i> , 2014 , 104, 352-7	4.3	82
471	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E μ -TCL1 CLL mouse model. <i>Blood</i> , 2015 , 126, 212-21	2.2	82
470	Blocking autophagy prevents bortezomib-induced NF- κ B activation by reducing I- κ B β degradation in lymphoma cells. <i>PLoS ONE</i> , 2012 , 7, e32584	3.7	80
469	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. <i>Leukemia</i> , 2013 , 27, 362-9	10.7	80
468	Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. <i>Journal of Experimental Medicine</i> , 1996 , 184, 365-76	16.6	79
467	How I treat indolent lymphoma. <i>Blood</i> , 2007 , 109, 4617-26	2.2	78
466	SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
465	Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 1709-19	2.2	77
464	Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 241-53	4.7	76
463	Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2654-61	2.2	75
462	Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 21-7	2	75

461	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
460	T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. <i>Blood</i> , 2002 , 100, 167-73	2.2	73
459	Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. <i>Blood</i> , 2008 , 111, 2797-805	2.2	72
458	Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. <i>Blood</i> , 2015 , 125, 4060-8	2.2	71
457	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2117-2125	4.7	70
456	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009 , 113, 2298-301	2.2	69
455	A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. <i>Stem Cells Translational Medicine</i> , 2014 , 3, 520-9	6.9	67
454	Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 207-35	3.1	67
453	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 262-8	4.7	63
452	Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. <i>British Journal of Haematology</i> , 2020 , 190, e64-e67	4.5	62
451	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018 , 5, e563-e598	14.6	62
450	Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. <i>Blood</i> , 2008 , 111, 5101-8	2.2	62
449	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009 , 23, 1858-66	10.7	61
448	Versatile humanized niche model enables study of normal and malignant human hematopoiesis. <i>Journal of Clinical Investigation</i> , 2017 , 127, 543-548	15.9	60
447	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1530-1542	21.7	59
446	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018 , 32, 1261-1265	10.7	58
445	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001 , 29, 183-93	3.1	57
444	GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 1989 , 4, 49-54	4.4	56

443	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014 , 123, 4101-10	2.2	55
442	Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. <i>Blood</i> , 2001 , 98, 2999-3005	2.2	55
441	Empirical inference of circuitry and plasticity in a kinase signaling network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 7719-24	11.5	53
440	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 399-406	18.8	52
439	Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1057-65	4.7	52
438	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016 , 101, 531-40	6.6	52
437	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 417-23	1.9	51
436	Rediscovering alemtuzumab: current and emerging therapeutic roles. <i>British Journal of Haematology</i> , 2009 , 144, 818-31	4.5	51
435	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 42-8	2.2	50
434	Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 ex vivo expansion. <i>Journal of Immunotherapy</i> , 2010 , 33, 684-96	5	50
433	Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. <i>Blood</i> , 2003 , 102, 4520-6	2.2	50
432	The role of the tumor microenvironment in hematological malignancies and implication for therapy. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 1581-96	2.8	49
431	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019 , 570, 474-479	50.4	47
430	Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. <i>British Journal of Haematology</i> , 2014 , 164, 526-35	4.5	47
429	Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18078-83	11.5	47
428	Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. <i>Annals of Hematology</i> , 2009 , 88, 121-32	3	47
427	Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. <i>Blood</i> , 1999 , 94, 3325-33	2.2	46
426	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014 , 99, 715-25	6.6	44

425	Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. <i>Blood</i> , 2007 , 109, 3989-97	2.2	44
424	CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1152-9	2.2	44
423	Single cell analysis of clonal architecture in acute myeloid leukaemia. <i>Leukemia</i> , 2019 , 33, 1113-1123	10.7	44
422	Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. <i>Journal of Immunology</i> , 1997 , 159, 3156-67	5.3	44
421	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 2765-2775	2.2	42
420	Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015 , 136, 2761-74	7.5	41
419	Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2005 , 129, 499-510	4.5	41
418	Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. <i>Haematologica</i> , 2015 , 100, 363-9	6.6	40
417	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 3079-88	2.2	39
416	Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. <i>Blood</i> , 2008 , 111, 3137-44	2.2	39
415	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018 , 180, 666-679	4.5	38
414	T-cell function in chronic lymphocytic leukaemia. <i>Seminars in Cancer Biology</i> , 2010 , 20, 431-8	12.7	38
413	Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. <i>Blood</i> , 1996 , 88, 41-8	2.2	38
412	Stem cell transplantation in chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 53-8	4.7	37
411	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , 1993 , 81, 3449-57	2.2	37
410	Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. <i>Seminars in Hematology</i> , 2014 , 51, 228-34	4	35
409	A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 1999 , 5, 2392-8	12.9	35
408	How and when I do allogeneic transplant in CLL. <i>Blood</i> , 2018 , 132, 31-39	2.2	34

407	Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. <i>British Journal of Haematology</i> , 2014 , 164, 790-803	4.5	34
406	Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. <i>Blood</i> , 2004 , 103, 4602-9	2.2	34
405	CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. <i>Medical and Pediatric Oncology</i> , 2000 , 35, 677-82		34
404	Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. <i>Blood</i> , 2014 , 123, 2066-74	2.2	33
403	NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016 , 175, 43-54	4.5	32
402	Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 9-16	4.7	32
401	Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. <i>Blood</i> , 2004 , 104, 4002-9	2.2	31
400	Chronic lymphocytic leukemia: planning for an aging population. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1389-94	3.5	30
399	The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. <i>British Journal of Haematology</i> , 2010 , 151, 167-78	4.5	28
398	Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. <i>Experimental Hematology</i> , 2002 , 30, 703-10	3.1	28
397	Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. <i>Blood</i> , 1989 , 73, 340-4	2.2	27
396	Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. <i>Cancer Research</i> , 2001 , 61, 4761-5	10.1	27
395	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. <i>Histopathology</i> , 2013 , 62, 860-75	7.3	26
394	Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. <i>Current Opinion in Oncology</i> , 2010 , 22, 424-30	4.2	26
393	A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. <i>British Journal of Haematology</i> , 2001 , 113, 455-60	4.5	26
392	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017 , 102, 1413-1423	6.6	25
391	Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2790-6	2.2	25
390	The evolving role of alemtuzumab in management of patients with CLL. <i>Leukemia</i> , 2005 , 19, 2147-52	10.7	25

389	Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. <i>British Journal of Haematology</i> , 1989 , 73, 152-7	4.5	25
388	Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 601-7	4.7	24
387	Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. <i>Journal of Molecular Medicine</i> , 1999 , 77, 259-65	5.5	24
386	Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3038-3050	15.9	24
385	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2018 , 32, 1818-1822	10.7	23
384	The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. <i>Blood</i> , 1994 , 84, 1402-7	2.2	23
383	Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. <i>Blood</i> , 1993 , 82, 1366-76	2.2	23
382	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020 , 7, e50-e60	14.6	23
381	Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). <i>Leukemia</i> , 2017 , 31, 1240-1243	10.7	22
380	The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. <i>Nature Communications</i> , 2017 , 8, 1679	17.4	22
379	Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. <i>Experimental Hematology</i> , 2002 , 30, 529-36	3.1	22
378	Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 95, 2651-8	2.2	22
377	Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. <i>Leukemia</i> , 2017 , 31, 2085-2093	10.7	21
376	Molecular profiling in CLL. <i>Hematology American Society of Hematology Education Program</i> , 2008 , 444-9	3.1	21
375	High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution. <i>PLoS ONE</i> , 2015 , 10, e0134833	3.7	21
374	Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. <i>Blood</i> , 1996 , 87, 4887-93	2.2	21
373	Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. <i>Blood</i> , 1998 , 91, 244-51	2.2	21
372	Cancer Burden Is Controlled by Mural Cell-β-Integrin Regulated Crosstalk with Tumor Cells. <i>Cell</i> , 2020 , 181, 1346-1363.e21	56.2	20

371	Immune reconstitution in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 13-20	4.4	20
370	A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, e1-15	2.2	20
369	CD40 activation: potential for specific immunotherapy in B-CLL. <i>Annals of Oncology</i> , 2004 , 15, 853-7	10.3	20
368	Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. <i>Oncotarget</i> , 2014 , 5, 11653-68	3.3	20
367	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 989-98	3.8	20
366	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. <i>Cancer Research</i> , 2016 , 76, 2082-6	10.1	19
365	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018 , 93, 1402-1410	7.1	19
364	Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 459-64	11.5	19
363	Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009 , 33, 368-76	2.7	19
362	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018 , 132, 182-182	2.2	19
361	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. <i>Blood</i> , 2016 , 128, 72-81	2.2	19
360	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , 2019 , 63, 207-13	3.8	18
359	Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. <i>British Journal of Haematology</i> , 2009 , 146, 574-6	4.5	18
358	Stem cell transplantation for non-Hodgkin's lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 1051-79, xi	3.1	18
357	Salvage therapy for CLL and the role of stem cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 292-8	3.1	18
356	Attainment of molecular remission: a worthwhile goal?. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1532-4	2.2	18
355	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. <i>Blood</i> , 2020 , 136, 37-39	2.2	18
354	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015 , 126, 494-494	2.2	18

353	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 27816-31	3.3	18
352	Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011 , 117, 116-24	6.4	17
351	Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. <i>Haematologica</i> , 2009 , 94, 148-50	6.6	17
350	Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. <i>American Journal of Hematology</i> , 1997 , 56, 45-51	7.1	17
349	Emerging therapy for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 139, 635-44	4.5	17
348	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 3978-3978	2.2	17
347	Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. <i>Cancer Journal (Sudbury, Mass)</i> , 2000 , 6, 146-50	2.2	17
346	Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. <i>Leukemia</i> , 2017 , 31, 734-738	10.7	16
345	Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. <i>Frontiers in Immunology</i> , 2018 , 9, 646	8.4	16
344	SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. <i>Blood</i> , 2011 , 117, 3147-50	2.2	16
343	Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. <i>Journal of Clinical Oncology</i> , 2006 , 24, e23-5	2.2	16
342	Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. <i>Leukemia</i> , 2004 , 18, 953-61	10.7	16
341	Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. <i>Leukemia Research</i> , 2004 , 28, 139-47	2.7	16
340	Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016 , 16, 689-700	2.8	16
339	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. <i>Blood</i> , 2021 , 138, 370-381	2.2	16
338	Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). <i>Current Hematologic Malignancy Reports</i> , 2016 , 11, 29-36	4.4	16
337	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1291-9	1.9	16
336	Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. <i>Blood</i> , 1997 , 89, 3806-16	2.2	16

335	Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. <i>Blood</i> , 1997 , 90, 4212-21	2.2	16
334	In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. <i>Blood</i> , 1997 , 90, 4297-306	2.2	16
333	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017 , 96, 253-259	3	15
332	Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. <i>Oncogene</i> , 2017 , 36, 2762-2774	9.2	15
331	Microenvironment abnormalities and lymphomagenesis: Immunological aspects. <i>Seminars in Cancer Biology</i> , 2015 , 34, 36-45	12.7	15
330	Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract. <i>British Journal of Haematology</i> , 2012 , 157, 403-7	4.5	15
329	The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas. <i>Hematological Oncology</i> , 1987 , 5, 281-93	1.3	15
328	Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004 , 45, 315-20	1.9	15
327	High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1998 , 28, 219-30	1.9	15
326	Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. <i>Journal of Oncology Practice</i> , 2017 , 13, 371-377	3.1	14
325	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1743-8	1.9	14
324	Chronic lymphocytic leukemia: an update on biology and treatment. <i>Current Oncology Reports</i> , 2011 , 13, 379-85	6.3	14
323	CD40 ligand therapy of lymphoma patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4351-3	2.2	14
322	Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. <i>Current Opinion in Oncology</i> , 1998 , 10, 542-7	4.2	14
321	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016 , 128, 615-615	2.2	14
320	IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. <i>Blood</i> , 2020 , 135, 834-844	2.2	13
319	Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. <i>Haematologica</i> , 2018 , 103, 688-697	6.6	13
318	Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. <i>Current Pharmaceutical Design</i> , 2012 , 18, 3389-98	3.3	13

317	Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity. <i>Current Pharmaceutical Design</i> , 2003 , 9, 1889-903	3.3	13
316	Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. <i>Blood</i> , 1991 , 77, 1837-44	2.2	13
315	Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. <i>Blood</i> , 2010 , 116, 697-697	2.2	13
314	Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019 , 19, 82	3	12
313	The role of the tumor microenvironment in HIV-associated lymphomas. <i>Biomarkers in Medicine</i> , 2015 , 9, 473-82	2.3	12
312	Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. <i>Blood Cancer Journal</i> , 2016 , 6, e404	7	12
311	Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, S63-70	4.7	12
310	Autografting CLL: the game is over!. <i>Blood</i> , 2011 , 117, 6057-8	2.2	12
309	Targeting the microenvironment. <i>Leukemia and Lymphoma</i> , 2010 , 51 Suppl 1, 34-40	1.9	12
308	Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Blood</i> , 2021 , 137, 111-121	10.3	12
307	Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. <i>Blood</i> , 2018 , 132, 1597-1597	2.2	12
306	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. <i>Blood</i> , 1996 , 88, 2780-6	2.2	12
305	Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. <i>Blood</i> , 1997 , 90, 549-61	2.2	12
304	The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. <i>Nuclear Medicine Communications</i> , 2014 , 35, 311-5	1.6	11
303	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. <i>Haematologica</i> , 2013 , 98, 620-5	6.6	11
302	Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. <i>Blood Reviews</i> , 2010 , 24, 135-41	11.1	11
301	Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. <i>Blood</i> , 2005 , 105, 2235-8	2.2	11
300	Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. <i>British Journal of Haematology</i> , 2005 , 131, 185-92	4.5	11

299	Monitoring disease in lymphoma and CLL patients using molecular techniques. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 179-95	4.2	11
298	Bone marrow purging for autologous bone marrow transplantation. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 2, 141-8	1.9	11
297	Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 844-851	4.5	11
296	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020 , 34, 522-532	10.7	11
295	Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice. <i>Scientific Reports</i> , 2019 , 9, 13478	4.9	10
294	Immunotherapeutic strategies including transplantation: eradication of disease. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 151-7	3.1	10
293	Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 429-34	4.7	10
292	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020 , 136, 17-18	2.2	10
291	Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. <i>Blood</i> , 1998 , 91, 4496-503	2.2	10
290	Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. <i>Cell Death and Disease</i> , 2019 , 10, 330	9.8	9
289	Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. <i>British Journal of Haematology</i> , 2012 , 157, 201-4	4.5	9
288	Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. <i>PLoS ONE</i> , 2012 , 7, e51390	3.7	9
287	Vaccine- and immune-based therapy in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2006 , 33, 220-9	5.5	9
286	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 4196-4196	2.2	9
285	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA8502-LBA8502	2.2	9
284	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017 , 35, 397-407	1.3	8
283	Stabilization of β -catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020 , 39, 2934-2947	9.2	8
282	Acute myeloid leukemia xenograft success prediction: Saving time. <i>Experimental Hematology</i> , 2018 , 59, 66-71.e4	3.1	8

281	Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. <i>British Journal of Haematology</i> , 2013 , 162, 525-9	4.5	8
280	One step back but 2 steps forward. <i>Blood</i> , 2009 , 114, 3359-60	2.2	8
279	Vaccine therapy and chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 421-36	4.2	8
278	Stem-cell transplantation in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 513-27	4.2	8
277	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 445-445	2.2	8
276	Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.. <i>Blood</i> , 2004 , 104, 3487-3487	2.2	8
275	Stem Cell Transplantation for Refractory Crohn Disease--Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2620-1	27.4	7
274	T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. <i>British Journal of Haematology</i> , 2012 , 157, 580-5	4.5	7
273	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3031-7	1.9	7
272	The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. <i>Blood</i> , 1992 , 79, 489-94	2.2	7
271	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020 , 105, 1379-1390	6.6	7
270	A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery. <i>Pain</i> , 2019 , 160, 2691-2698	8	7
269	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. <i>Cell Reports</i> , 2019 , 27, 1461-1471.e4	10.6	6
268	Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC β subversion induces up-regulation of PKC η expression in B lymphocytes. <i>Haematologica</i> , 2015 , 100, 499-510	6.6	6
267	Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003 , 32, 681-6	4.4	6
266	Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. <i>Leukemia Research</i> , 2003 , 27, 859-63	2.7	6
265	Minimal residual disease in non-Hodgkin's lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 1996 , 50, 451-87.5		6
264	Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. <i>Blood</i> , 1992 , 80, 1083-9	2.2	6

263	Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 1543-1565	7.9	6
262	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016 , 101, 1144-1158	6.6	6
261	Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. <i>Supportive Care in Cancer</i> , 2017 , 25, 739-748	3.9	5
260	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014 , 207, 19-30	2.3	5
259	Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. <i>Journal of Immunological Methods</i> , 2009 , 348, 95-100	2.5	5
258	Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 952-3	2.2	5
257	Autologous hematopoietic transplantation for low-grade lymphomas. <i>Cytotherapy</i> , 2002 , 4, 205-15	4.8	5
256	The role of autologous bone marrow transplantation in the treatment of malignant disease. <i>Blood Reviews</i> , 1987 , 1, 193-200	11.1	5
255	Monitoring minimal residual disease. <i>Seminars in Oncology</i> , 1993 , 20, 143-55	5.5	5
254	Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.. <i>Blood</i> , 2009 , 114, 539-539	2.2	5
253	Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2514-2514	2.2	5
252	Obinutuzumab for the treatment of indolent lymphoma. <i>Future Oncology</i> , 2016 , 12, 1769-81	3.6	5
251	Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia. <i>Discovery Medicine</i> , 2013 , 16, 295-302	2.5	5
250	A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020 , 105, e164-e168	6.6	4
249	Dangerous power: mitochondria in CLL cells. <i>Blood</i> , 2014 , 123, 2596-7	2.2	4
248	Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone. <i>European Journal of Haematology</i> , 2014 , 92, 360-1	3.8	4
247	Cutaneous cryptococcosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 164, 467	4.5	4
246	Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89. <i>Leukemia and Lymphoma</i> , 1990 , 1, 157-62	1.9	4

245	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. <i>ESMO Open</i> , 2022 , 7, 100403	6	4
244	Mapping Low Molecular Weight Plasma Proteome of Chronic Lymphoblastic Leukemia Patients Using MALDI-TOF Mass Spectrometry.. <i>Blood</i> , 2004 , 104, 1910-1910	2.2	4
243	High Levels of Early Donor Chimerism and Treatment-Responsive Disease Predict Improved Progression-Free Survival Following Non-Myeloablative Transplantation for Advanced CLL.. <i>Blood</i> , 2005 , 106, 560-560	2.2	4
242	Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 2104-2104	2.2	4
241	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008 , 112, 972-972	2.2	4
240	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 1532-1532	2.2	4
239	Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8023-8023	2.2	4
238	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1087-1091	1.9	4
237	New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 586-94	0.6	4
236	Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.. <i>Science Signaling</i> , 2022 , 15, eabl7989	8.8	4
235	Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. <i>Journal of Biological Chemistry</i> , 2020 , 295, 5496-5508	5.4	3
234	The kiss of death in FL. <i>Blood</i> , 2011 , 118, 5365-6	2.2	3
233	No evidence for MUC 1-induced apoptosis. <i>Nature Medicine</i> , 1998 , 4, 1093	50.5	3
232	The Role of Growth Factors in Bone-Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1990 , 1, 87-93	1.9	3
231	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018 , 132, 5565-5565	2.2	3
230	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 ILLUMINATE. <i>Blood</i> , 2018 , 132, 691-691	2.2	3
229	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018 , 132, 4097-4097	2.2	3
228	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019 , 134, 4575-4575	2.2	3

227	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. <i>Blood</i> , 2004 , 104, 730-730	2.2	3
226	Fludarabine and Alemtuzumab Versus Fludarabine and Rituximab in the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from a Phase II Study.. <i>Blood</i> , 2005 , 106, 5046-5046	2.2	3
225	Successful Generation of Cytotoxic T-Cells That Kill CLL Cells Using Heteroclitic Peptides Is Independent of the Native Peptide Binding Affinity to HLA-A*0201.. <i>Blood</i> , 2005 , 106, 54-54	2.2	3
224	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 835-835	2.2	3
223	Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells.. <i>Blood</i> , 2008 , 112, 2333-2333	2.2	3
222	An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).. <i>Blood</i> , 2009 , 114, 3428-3428	2.2	3
221	Concurrent Follicular Lymphoma At Diagnosis Has a Negative Impact On The Outcome Of Patients With Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013 , 122, 4260-4260	2.2	3
220	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. <i>Blood</i> , 2016 , 128, 1087-1087	2.2	3
219	A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2547-2547	2.2	3
218	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the ILLUMINATE study. <i>Annals of Hematology</i> , 2021 , 100, 1733-1742	3	3
217	Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy. <i>Haematologica</i> , 2019 , 104, e42-e44	6.6	3
216	Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2018 , 180, 346-355	4.5	3
215	The role of stem cell transplant for lymphoma in 2017. <i>Hematological Oncology</i> , 2017 , 35 Suppl 1, 25-29	1.3	2
214	Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation. <i>Frontiers in Oncology</i> , 2020 , 10, 307	5.3	2
213	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1840-1843	4.4	2
212	No longer too exhausted to run. <i>Blood</i> , 2018 , 132, 464-465	2.2	2
211	Hanging tough: CMV-specific CD8+ T cells in CLL. <i>Blood</i> , 2014 , 123, 608-9	2.2	2
210	Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 109-19	4.2	2

209	A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 4161-4161	2.2	2
208	Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance. <i>Blood</i> , 2018 , 132, 58-58	2.2	2
207	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019 , 134, 347-347	2.2	2
206	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019 , 134, 324-324	2.2	2
205	Patients (Pts) Surviving Haploidentical Stem Cell Transplantation (SCT) after Ex Vivo Costimulatory Blockade To Induce Anergy Experience Few Long-Term Complications.. <i>Blood</i> , 2005 , 106, 599-599	2.2	2
204	Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2778-2778	2.2	2
203	Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.. <i>Blood</i> , 2006 , 108, 2839-2839	2.2	2
202	Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007 , 110, 181-181	2.2	2
201	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. <i>Blood</i> , 2008 , 112, 3125-3125	2.2	2
200	A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.. <i>Blood</i> , 2010 , 116, 3188-3188	2.2	2
199	An Immunohistochemical Score Based On CD68 and FOXP3 Expression In the Tumour Microenvironment at Diagnosis Defines Prognostic Groups In Both Early and Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 750-750	2.2	2
198	Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011 , 118, 1657-1657	2.2	2
197	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1794-1794	2.2	2
196	Activation of Mitochondrial STAT3 Increases Mitochondrial Respiration and Inhibits Oxidative Stress in Chronic Lymphocytic Leukemic Cells. <i>Blood</i> , 2011 , 118, 287-287	2.2	2
195	Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 976-976	2.2	2
194	T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment. <i>Blood</i> , 2013 , 122, 4120-4120	2.2	2
193	A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). <i>Blood</i> , 2021 , 138, 3543-3543	2.2	2
192	Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.. <i>Blood</i> , 2004 , 104, 4841-4841	2.2	2

191	Stromal Cells Protect B-CLL Cells from Killing by Antigen-Specific Cytotoxic T Cells.. <i>Blood</i> , 2006 , 108, 2814-2814	2.2	2
190	CD3+/CD56+ Cells, but Not Natural Killer T Cells, Are Increased in Peripheral Blood of Untreated Patients with Leukemia.. <i>Blood</i> , 2007 , 110, 1815-1815	2.2	2
189	Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment. <i>Blood</i> , 2019 , 134, 658-658	2.2	2
188	Stem cell transplantation for indolent lymphoma. <i>Current Opinion in Hematology</i> , 1999 , 6, 388-93	3.3	2
187	Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience. <i>British Journal of Haematology</i> , 2021 , 193, 420-423	4.5	2
186	Integrated OMICs unveil the bone-marrow microenvironment in human leukemia. <i>Cell Reports</i> , 2021 , 35, 109119	10.6	2
185	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2021 , 10, 4864-4873	4.8	2
184	Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. <i>British Journal of Haematology</i> , 2016 , 173, 165-9	4.5	2
183	Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer. <i>JAMA Network Open</i> , 2020 , 3, e2019304	10.4	1
182	Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2020 , 189, 603-604	4.5	1
181	Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 1055-71	3.1	1
180	Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma—response to Meissner et al. <i>British Journal of Haematology</i> , 2014 , 166, 615-6	4.5	1
179	Less expensive CARs?. <i>Cytotherapy</i> , 2012 , 14, 773-4	4.8	1
178	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 2013 , 17		1
177	The 3 Rs in CLL immune dysfunction. <i>Blood</i> , 2010 , 115, 2563-4	2.2	1
176	Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4864-5	2.2	1
175	Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients. <i>Expert Opinion on Medical Diagnostics</i> , 2008 , 2, 101-12		1
174	Role of autologous stem cell transplantation in chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2003 , 10, 306-11	3.3	1

173	Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. <i>Important Advances in Oncology</i> , 1994 , 117-29		1
172	Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab. <i>Blood</i> , 2018 , 132, 3296-3296	2.2	1
171	Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK. <i>Blood</i> , 2018 , 132, 3139-3139	2.2	1
170	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the GadoIn Study. <i>Blood</i> , 2018 , 132, 3139-3139	2.2	1
169	Quantitative Analysis of Minimal Residual Disease at the Completion of Induction Therapy Predicts Relapse in Children with B-Lineage Acute Lymphoblastic Leukemia in DFCI ALL Consortium Protocol 95-01.. <i>Blood</i> , 2004 , 104, 323-323	2.2	1
168	Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma. <i>Blood</i> , 2008 , 112, 885-885	2.2	1
167	Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2009 , 114, 2370-2370	2.2	1
166	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R β ull (NSG) Mice as a Model.. <i>Blood</i> , 2009 , 114, 2370-2370	2.2	1
165	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010 , 116, 1376-1376	2.2	1
164	TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma. <i>Blood</i> , 2010 , 116, 799-799	2.2	1
163	The PD1/PD-L1 Axis in the Classical Hodgkin Lymphoma Microenvironment: PD-1 Is Rarely Expressed but Identifies Patients with High-Risk Disease. <i>Blood</i> , 2011 , 118, 1560-1560	2.2	1
162	PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110 β Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients. <i>Blood</i> , 2011 , 118, 1654-1654	2.2	1
161	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 246-246	2.2	1
160	Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells. <i>Blood</i> , 2011 , 118, 951-951	2.2	1
159	Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2R β Null Mice. <i>Blood</i> , 2012 , 120, 1565-1565	2.2	1
158	Increased Tonic PI3K Signaling Through p110 β Can Limit the Efficacy of P110 β Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse. <i>Blood</i> , 2012 , 120, 1652-1652	2.2	1
157	IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model.. <i>Blood</i> , 2012 , 120, 2949-2949	2.2	1
156	Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. <i>Blood</i> , 2013 , 122, 1458-1458	2.2	1

155	TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 2426-2426	2.2	1
154	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1713-1713	2.2	1
153	Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1763-1763	2.2	1
152	Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets. <i>Blood</i> , 2016 , 128, 5265-5265	2.2	1
151	Discrimination of Long and Short Survival in Follicular Lymphoma (FL) Patients by Incidence of FOXP3 and Perifollicular Incidence of CD4 and CD7 Using Immunohistochemistry on Tissue Microarray (TMA) of Diagnostic Lymph Nodes (LN).. <i>Blood</i> , 2005 , 106, 603-603	2.2	1
150	CLL Cells in TCL1 Transgenic Mice Induce Similar Defects in CD4 and CD8 T Cells to Those Observed in Patients with CLL.. <i>Blood</i> , 2005 , 106, 50-50	2.2	1
149	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005 , 106, 2943-2943	2.2	1
148	Impaired Actin Polymerization Results in Defective Immunological Synapse Formation in T Cells in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 338-338	2.2	1
147	A Novel Non-Invasive Method of Detecting Galactomannan in Suspected Pulmonary Aspergillosis.. <i>Blood</i> , 2007 , 110, 3862-3862	2.2	1
146	Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT. <i>Blood</i> , 2019 , 134, 595-595	2.2	1
145	Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Suppressor Cells in CLL-Bearing Mice. <i>Blood</i> , 2019 , 134, 3032-3032	2.2	1
144	Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-B β Degradation. <i>Blood</i> , 2010 , 116, 116-116	2.2	1
143	Inhibition of Autophagy by Chloroquine Sensitises Lymphoma Cells to ABT-737-Induced Apoptosis. <i>Blood</i> , 2012 , 120, 1625-1625	2.2	1
142	Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD. <i>Blood</i> , 2021 , 137, 702-717	2.2	1
141	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. <i>IScience</i> , 2021 , 24, 102089	6.1	1
140	Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. <i>Nature Communications</i> , 2021 , 12, 5507	17.4	1
139	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021 , 12, 5395	17.4	1
138	Stem-cell transplantation for indolent lymphoma. <i>Seminars in Hematology</i> , 1999 , 36, 18-25	4	1

137	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
136	The role of BTK inhibitors on the tumor microenvironment in CLL.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	1
135	Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. <i>Blood</i> , 2021 , 138, 3726-3726	2.2	0
134	SKIP Is Underexpressed in AML Leading to Sphingosine Kinase Hypofunction. <i>Blood</i> , 2014 , 124, 5324-5324	2.2	0
133	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. <i>Blood</i> , 2016 , 128, 5199-5199	2.2	0
132	Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On EBV-CLL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo. <i>Blood</i> , 2012 , 120, 313-313	2.2	0
131	NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide. <i>Blood</i> , 2013 , 122, 4131-4131	2.2	0
130	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2392-2399	1.9	0
129	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2625-2636	1.9	0
128	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.. <i>Lancet Haematology</i> , 2022 , 9, e374-e384	14.6	0
127	B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. <i>HemaSphere</i> , 2022 , 6, e722	0.3	0
126	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022 , 6, e726	0.3	0
125	Restoring leukemia cell function from the inside out. <i>Blood</i> , 2017 , 129, 3137-3138	2.2	
124	Chronic lymphocytic leukemia 2017 , 123-130		
123	XV. Clinical aspects of transformed lymphoma. <i>Hematological Oncology</i> , 2015 , 33 Suppl 1, 80-3	1.3	
122	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2017 ,	10.7	
121	A shot in the arm for radiotherapy. <i>Blood</i> , 2013 , 121, 246-8	2.2	
120	2.17 Activation of STAT3 Increases Mitochondrial Respiration and Protects Mitochondria from Oxidative Damage in Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, S170-S171	2	

119	Transplantation in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 56-63	4.4
118	Indolent B-cell malignancies: immune recognition and antiself. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S77-83	1.9
117	Death of follicular lymphoma cells: the long and the short of it. <i>Blood</i> , 2004 , 103, 374-374	2.2
116	Immunotherapy in the B-cell lymphomas. <i>Cytotherapy</i> , 2002 , 4, 439-40	4.8
115	Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings. <i>Blood</i> , 2020 , 136, 37-38	2.2
114	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Unstable Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2
113	Educational Needs for Physicians 2022 , 203-206	
112	Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL 2022 , 123-125	
111	Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 3462-3462	2.2
110	Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia. <i>Blood</i> , 2021 , 138, 324-324	2.2
109	Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC-driven Lymphoma. <i>Blood</i> , 2021 , 138, 717-717	2.2
108	Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T. <i>Blood</i> , 2021 , 138, 2787-2787	2.2
107	Distinct VDJ-H Gene Usage between Mutated and Unmutated Patients in B-CLL: Implications for Pathogenesis and Correlation with Clinical Outcome.. <i>Blood</i> , 2004 , 104, 970-970	2.2
106	Temporal Gene Expression after BCR-Crosslinking Based upon Zap70 Related Genomic Features.. <i>Blood</i> , 2004 , 104, 2795-2795	2.2
105	A Phase II Study of Xcellerated T Cells in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2004 , 104, 4640-4640	2.2
104	Somatic Hypermutation Does Not Increase the Binding Affinity of Ig Derived Peptides to MHC Class I or II - Implications for Ig Peptide Vaccination Strategies.. <i>Blood</i> , 2004 , 104, 960-960	2.2
103	Molecular Analysis of T-Cell Receptor Gene Rearrangements in Children with T-Cell Acute Lymphoblast Leukemia on DFCI ALL Consortium Protocol 95-01.. <i>Blood</i> , 2004 , 104, 1084-1084	2.2
102	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004 , 104, 185-185	2.2

101	Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction.. <i>Blood</i> , 2004 , 104, 5243-5243	2.2
100	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004 , 104, 300-300	2.2
99	Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.. <i>Blood</i> , 2004 , 104, 956-956	2.2
98	Gene Expression Profiling Identifies Similar CD4+ and CD8+ T Cell Defects in TCL1 Transgenic Mice after Development of CLL to Those Observed in Patients with CLL.. <i>Blood</i> , 2004 , 104, 180-180	2.2
97	Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network.. <i>Blood</i> , 2004 , 104, 1128-1128	2.2
96	Cell Contact with CLL Cells Induces Defects in T Cell Differentiation and Effector Pathways: Impact of Silencing Specific Cytokine Production.. <i>Blood</i> , 2004 , 104, 955-955	2.2
95	In Vivo Demonstration of Donor Idiotype Specific T Cells That Kill Primary CLL Cells Post Allogeneic Transplant.. <i>Blood</i> , 2005 , 106, 62-62	2.2
94	Increased CD68 and Decreased CD4 Expressing Cells in Tissue Microarray (TMA) in Diagnostic Lymph Node Biopsies Are Associated with Poor Outcome in CLL/SLL.. <i>Blood</i> , 2006 , 108, 2781-2781	2.2
93	Utilisation of Stem Cell Transplantation for Lymphoplasmacytic Lymphoma in the UK.. <i>Blood</i> , 2006 , 108, 2980-2980	2.2
92	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , 2006 , 108, 3041-3041	2.2
91	Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.. <i>Blood</i> , 2006 , 108, 2774-2774	2.2
90	Dynamic Assessment of Apoptosis for In Vitro Design of Bortezomib Combination Therapies for Lymphoid Malignancies.. <i>Blood</i> , 2006 , 108, 2494-2494	2.2
89	Bax Degradation Activity Is a Novel Poor Prognosis Marker of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007 , 110, 3087-3087	2.2
88	Temporal Proteomic Analysis of CLL B Cell Response to Antigen Receptor Stimulation.. <i>Blood</i> , 2007 , 110, 1134-1134	2.2
87	SAGE Analysis Demonstrates Increased Expression of TOSO Contributing to Fas Mediated Resistance in CLL.. <i>Blood</i> , 2007 , 110, 1121-1121	2.2
86	Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.. <i>Blood</i> , 2007 , 110, 740-740	2.2
85	High Frequency of Surface Immunoglobulin IgG in B-Cell Chronic Lymphocytic Leukaemia.. <i>Blood</i> , 2007 , 110, 4685-4685	2.2
84	CLL Cell Proliferation and IL-6 Production Are Regulated by CD160 - MHC Class I Interactions Offering New Therapeutic Targets.. <i>Blood</i> , 2007 , 110, 1126-1126	2.2

83	Angiogenesis Assessed in Tissue Microarrays of Diagnostic Follicular Lymphoma Correlates with Outcome.. <i>Blood</i> , 2007 , 110, 2609-2609	2.2
82	Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions. <i>Blood</i> , 2017 , 130, 77-77	2.2
81	The Treg/Th17 Axis Is Skewed in Classical Hodgkin Lymphoma By PDL1+Ve but Not PDL1-Ve Lymphoma Cells and By Lymphoma MHC Class 2 Expression.. <i>Blood</i> , 2018 , 132, 4124-4124	2.2
80	Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway. <i>Blood</i> , 2018 , 132, 588-588	2.2
79	Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. <i>Blood</i> , 2018 , 132, 4419-4419	2.2
78	Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology. <i>Blood</i> , 2018 , 132, 4101-4101	2.2
77	Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2863-2863	2.2
76	Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib. <i>Blood</i> , 2018 , 132, 3138-3138	2.2
75	B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2018 , 132, 3121-3121	2.2
74	Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model. <i>Blood</i> , 2018 , 132, 4537-4537	2.2
73	The EBTCL1 Mouse Model of Chronic Lymphocytic Leukemia 2019 , 2213-2241	
72	Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7514-7514	2.2
71	CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS. <i>Blood</i> , 2019 , 134, 249-249	2.2
70	The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets. <i>Blood</i> , 2019 , 134, 5240-5240	2.2
69	CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34+ Cells. <i>Blood</i> , 2019 , 134, 2517-2517	2.2
68	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. <i>Blood</i> , 2019 , 134, 2769-2769	2.2
67	AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8614-TPS8614	2.2
66	Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. <i>Blood</i> , 2014 , 124, 3298-3298	2.2

- 65 Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors. *Blood*, **2014**, 124, 1309-1309 2.2
- 64 Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7. *Blood*, **2014**, 124, 716-716 2.2
- 63 The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eμ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. *Blood*, **2014**, 124, 1966-1966 2.2
- 62 High Resolution Genomic Profiling of Primary Ultra High Risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. *Blood*, **2014**, 124, 3288-3288 2.2
- 61 Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfunction and CLL Development in the TCL1 Adoptive Transfer Mouse Model. *Blood*, **2014**, 124, 717-717 2.2
- 60 Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas. *Blood*, **2014**, 124, 3007-3007 2.2
- 59 Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile. *Blood*, **2014**, 124, 1103-1103 2.2
- 58 Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 617-617 2.2
- 57 Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors. *Blood*, **2016**, 128, 840-840 2.2
- 56 Alloresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide. *Blood*, **2016**, 128, 5714-5714 2.2
- 55 In Chronic Lymphocytic Leukemia T7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. *Blood*, **2016**, 128, 971-971 2.2
- 54 Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells. *Methods in Molecular Biology*, **2017**, 1584, 533-544 1.4
- 53 Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. *Blood*, **2008**, 112, 543-543 2.2
- 52 Defective T Cell Migration in Chronic Lymphocytic Leukemia Is Repaired by Lenalidomide. *Blood*, **2008**, 112, 3117-3117 2.2
- 51 Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma. *Blood*, **2008**, 112, 2822-2822 2.2
- 50 Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death!.. *Blood*, **2008**, 112, 2088-2088 2.2
- 49 A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction. *Blood*, **2008**, 112, 30-30 2.2
- 48 Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis.. *Blood*, **2008**, 112, 1186-1186 2.2

47	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2905-2905	2.2
46	Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease.. <i>Blood</i> , 2008 , 112, 2109-2109	2.2
45	Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 2663-2663	2.2
44	Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling.. <i>Blood</i> , 2009 , 114, 4372-4372	2.2
43	Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis.. <i>Blood</i> , 2009 , 114, 4371-4371	2.2
42	CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies.. <i>Blood</i> , 2009 , 114, 4382-4382	2.2
41	Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 3029-3029	2.2
40	Defective LFA-1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway. <i>Blood</i> , 2010 , 116, 914-914	2.2
39	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. <i>Blood</i> , 2010 , 116, 924-924	2.2
38	Functional Screening Studies Identify Combinational Activity of PD-L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 696-696	2.2
37	Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells. <i>Blood</i> , 2010 , 116, 3598-3598	2.2
36	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. <i>Blood</i> , 2010 , 116, 2453-2453	2.2
35	Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis. <i>Blood</i> , 2010 , 116, 141-141	2.2
34	Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma.. <i>Blood</i> , 2010 , 116, 3459-3459	2.2
33	A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma. <i>Blood</i> , 2010 , 116, 2388-2388	2.2
32	Physician Scientists In Hematology: Hematologists' Experiences of Research and Recruitment to Academia - A Mixed Methods, Qualitative Approach. <i>Blood</i> , 2010 , 116, 2570-2570	2.2
31	T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus. <i>Blood</i> , 2011 , 118, 1780-1780	2.2
30	HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. <i>Blood</i> , 2011 , 118, 3646-3646	2.2

- 29 Impact of Tumor Infiltrating T Cells in Patients with Follicular Lymphoma At Diagnosis. *Blood*, **2011**, 118, 769-769 2.2
- 28 Chronic Lymphocytic Leukemia Cells Co-Opt CD200, CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse. *Blood*, **2011**, 118, 802-802 2.2
- 27 The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. *Blood*, **2011**, 118, 502-502 2.2
- 26 Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy,. *Blood*, **2011**, 118, 3645-3645 2.2
- 25 Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival. *Blood*, **2011**, 118, 2663-2663 2.2
- 24 Autocrine IL-6 Production Indicates the Level of Activated STAT3 and NF-Kb of Chronic Lymphocytic Leukemia Cells. *Blood*, **2011**, 118, 1784-1784 2.2
- 23 Transplant in chronic lymphocytic leukemia: to do it or not and if so, when and how?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 399-404 7.1
- 22 Genetics of Teenage and Young Adult Acute Lymphoblastic T-Cell Leukaemia.. *Blood*, **2012**, 120, 2521-2521 2.2
- 21 High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. *Blood*, **2012**, 120, 545-545 2.2
- 20 Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide. *Blood*, **2012**, 120, 564-564 2.2
- 19 The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift. *Blood*, **2012**, 120, 1580-1580 2.2
- 18 Assessment of Bone Marrow Involvement by FDG-PET in Patients with Follicular Lymphoma. *Blood*, **2012**, 120, 5108-5108 2.2
- 17 Anergic Response to B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: The Differing Roles of IgD and IgM in the Microenvironment and Peripheral Blood.. *Blood*, **2012**, 120, 2889-2889 2.2
- 16 Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. *Blood*, **2012**, 120, 145-145 2.2
- 15 HMGB1 Activates TLR9/RAGE Signalling Pathway and Sustains Chronic Lymphocytic Leukemic Cell in Vitro Survival. *Blood*, **2012**, 120, 3860-3860 2.2
- 14 The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. *Blood*, **2012**, 120, 3865-3865 2.2
- 13 Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma. *Blood*, **2012**, 120, 1572-1572 2.2
- 12 The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy.. *Blood*, **2012**, 120, 3174-3174 2.2

- 11 The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. *Blood*, **2012**, 120, 790-790 2.2
- 10 Psychosocial Factors and Impact Of Cancer In British Long-Term Haematological Cancer Survivors. *Blood*, **2013**, 122, 2943-2943 2.2
- 9 Loss of Imprinting at the 14q32 Domain Leads to MicroRNA Overexpression in Acute Promyelocytic Leukemia. *Blood*, **2013**, 122, 2494-2494 2.2
- 8 Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues. *Blood*, **2013**, 122, 115-115 2.2
- 7 Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility. *Blood*, **2013**, 122, 4159-4159 2.2
- 6 Graft-versus-host disease: a case report of a rare but reversible cause of constrictive pericarditis. *European Heart Journal - Case Reports*, **2020**, 4, 1-5 0.9
- 5 Dynamic contrast-enhanced magnetic resonance imaging quantification of leukemia-induced changes in bone marrow vascular function. *Haematologica*, **2021**, 106, 2281-2286 6.6
- 4 Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules. *Molecular Therapy*, **2016**, 24, 1126-1134 11.7
- 3 The E_HTCL1 Mouse Model of Chronic Lymphocytic Leukemia **2019**, 1-29
- 2 Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2021**, 195, e131-e134 4.5
- 1 Bone marrow transplantation for low-grade B-cell malignancies. *Current Opinion in Oncology*, **1997**, 9, 117-21 4.2